SCHEMBL13765751

SCHEMBL13765751

Cc1ccc(-c2nc(Cl)nc3[nH]cnc23)c2ccccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.36
CYP1A2 P05177 1/20 0.35
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 3/20 0.35
PIM1 P11309 2/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
JAK2 O60674 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
PAK4 O96013 1/20 0.33
ABL1 P00519 1/20 0.33
CSF1R P07333 1/20 0.33
RET P07949 1/20 0.33
IGF1R P08069 1/20 0.33
MET P08581 1/20 0.33
PDGFRB P09619 1/20 0.33
FGFR1 P11362 1/20 0.33
PDGFRA P16234 1/20 0.33
PRKACA P17612 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13765750 0.81 HSP90AB1 (0.40) PARP1ALDH1A1KDM4EPIM1PAK4
SCHEMBL13765756 0.81 HSP90AB1 (0.50) ABL1HSP90AB1XDH
SCHEMBL13765757 0.78 HSP90AB1 (0.48) PAK4ABL1MAPK14HSP90AB1XDH
SCHEMBL13765755 0.77 KDM4E (0.35) PARP1ALDH1A1KDM4EPIM1PAK4
SCHEMBL14316035 0.76 ALDH1A1 (0.38) PARP1ALDH1A1KDM4EXDHMAPT
SCHEMBL13765758 0.75 KDM4E (0.50) ALDH1A1KDM4EJAK2MAPTLMNA
SCHEMBL4089680 0.73 DPP4 (0.46) HSP90AB1MAPTHPGD
SCHEMBL15860229 0.72 KDM4E (0.59) CYP1A2ALDH1A1KDM4EMAPTLMNA
SCHEMBL4259002 0.72 XDH (0.32) CYP1A2ALDH1A1KDM4ERETHSP90AB1
SCHEMBL13765754 0.69 CYP11B1 (0.41) CYP1A2ALDH1A1KDM4EMAPK8MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer HSP90AA1, HSP90AB1, HSP90AB2P PARP1 2314/4885CYP1A2 1171/4885ALDH1A1 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.